Earnings Shortfall at アドメディカ and Recognition of an Impairment Loss
First written in FY2025-H1. 2 of 5 entries say "Achieved", first in FY2026-H1. Latest entry: 2026-07-14.
The whole theme swung hardest in 2026: 17 of 32 companies on the "Worse" side.
0 other companies' latest entry also says "Achieved".
- 2026-07-14AchievedEarningsSuggests it is closing out
「Because the distribution of residual assets was completed in May 2026, effectively completing the liquidation procedures」
The company stated that AdMedica’s liquidation procedures had been completed. - FY2026-H1AchievedAnnual report
「株式会社アドメディカ, formerly our consolidated subsidiary, had been in liquidation after the Board of Directors resolved to dissolve it at a meeting held on 20 November 2025. As the distribution of its residual assets was completed in May 2026 and the substantive liquidation procedures were completed, it has been excluded from the scope of consolidation from the current interim consolidated accounting period.」
Regarding アドメディカ, following revenue shortfalls and impairment losses incurred through the previous fiscal year, the distribution of residual assets and the substantive liquidation procedures were completed in May 2026. - 2026-04-13MitigatedFinancial Results PresentationSuggests it is closing out
「Short-term borrowings and cash and deposits declined as acquisition financing was repaid following the resolution to dissolve AdMedica Co., Ltd.」
The company repaid borrowings related to acquisition financing following the resolution to dissolve AdMedica. This indicates that the financial arrangements associated with the dissolution are progressing. - FY2025WorsenedAnnual report
「Because we determined that the earnings originally anticipated could no longer be generated and resolved on 20 November 2025, following further consideration, to dissolve and liquidate the company, the carrying amounts of goodwill and customer-related assets were reduced to their recoverable amounts, and the resulting decrease of ¥812,215 thousand was recognized as an impairment loss and recorded as an extraordinary loss.」
Regarding アドメディカ, the impairment loss expanded from ¥659.325 million in FY2025-H1 to a full-year impairment loss of ¥812.215 million on goodwill and customer-related assets, and the dissolution and liquidation were resolved on 20 November 2025. - FY2025-H1MaterialisedAnnual report
「Regarding the goodwill and customer-related assets of 株式会社アドメディカ, acquired in 2024, a review of the business plan was conducted during the current interim consolidated accounting period based on the reallocation of resources across the group. As a result, because 株式会社アドメディカ, our consolidated subsidiary, could no longer generate the earnings originally anticipated, its carrying amount was reduced to the recoverable amount, and the resulting decrease of ¥659,325 thousand was recognized as an impairment loss and recorded as an extraordinary loss.」
As アドメディカ could no longer generate the earnings originally anticipated, impairment losses were actually recognized for goodwill of ¥268,604 thousand and customer-related assets of ¥390,720 thousand, totaling ¥659,325 thousand. The recoverable amount was calculated by discounting future cash flows at 10.53%.